On June 3, 2024, the annual production area cooperation meeting of China Medico was held as scheduled in Yuncheng, Shanxi, the birthplace of culture.
Leaders from Japan's Tsumura, Ping An Tsumura, Shenzhen Tsumura, China Medico, and Hiramura Pharmaceutical, as well as the heads of more than 60 origin companies attended the meeting.
▲Mr.Hirate, General Manager of the Tsumura Crude Drugs Headquarters in Japan
Mr.Hirate, General Manager of the Tsumura Crude Drugs Headquarters in Japan, gave an introduction entitled "Vision and Strategic Tasks of the Crude Drugs Headquarters 2023", elaborating on the 2023 financial results and the vision of the 2031 Crude Drugs Headquarters, and gave hope that we will grow with the production area, continue to improve the value of crude drugs, alleviate patients' pain, and contribute to human health.
▲Mr.Suyama , General Manager of the Crude Drug Production Management Department of the Tsumura Crude Drugs Headquarters in Japan
Mr.Suyama , General Manager of the Crude Drug Production Management Department of the Tsumura Crude Drugs Headquarters in Japan, introduced the GACP management policy and related issues, emphasizing the Tsumura quality policy, pesticide management, resume registration, etc., and hoped to strictly adhere to the quality standards of medicinal materials together with the local companies.
▲Chang Yusong, sales manager of Pingcun Pharmaceutical
At the meeting, Chang Yusong, sales manager of Pingcun Pharmaceutical, gave a detailed introduction and recommendation of the existing series of health products.
▲Zhang Naiwu, director of the planting management department of China Medico
Zhang Naiwu, director of the planting management department of China Medico, evaluated the GACP production group in 2023, and made a detailed report on ensuring the stability and uniformity of goods, ensuring the safety and reliability of crude drugs, implementing measures, and applying the cultivation management system, reiterating the company's quality standard requirements, and disclosing the relevant problems in the process.
▲Zhang Xu, Director of the Quality Management Department of China Medico
Zhang Xu, Director of the Quality Management Department of China Medico, summarized the quality of the goods in 2023 and elaborated on the relevant matters related to the expected cooperation of the production areas in 2024.
▲Yao Xionghui, Director of China Medico Procurement Department
Yao Xionghui, Director of China Medico Procurement Department, summarized the business situation of the Procurement Department, and gave a detailed description of the completion of the main work in 2023, the existing problems and the direction of work in 2024.
Based on the actual performance of the producing companies in the past year from the five dimensions of contract execution, quality management, GACP management, export support, and business cooperation, the Planting Management Department selected 10 "Excellence Awards for the Application of Cultivation Management System" and 1 "GACP Excellent Production Group Award"; The Purchasing Department selected 1 "Business Contribution Award" and 1 "Special Award for Decoction Piece Business"; Two "Excellent Origin Company Awards" were comprehensively selected, and these outstanding origin companies were commended and rewarded on the spot, encouraging them to continue to work hard to create better results, and at the same time encouraging other origin companies to keep up with excellence and develop together.
▲the exchange and discussion session
In the exchange and discussion session, the heads of the companies in each production area asked questions about the problems and existing problems encountered in the work, and the relevant leaders of Tsumura and China Medico in Japan answered the questions in detail for the production companies and actively helped the production companies to solve problems.
▲Hiroki Yamaji, director of the cultivation technology development department of the Tsumura Crude Drug Headquarters in Japan
During the meeting, Hiroki Yamaji, director of the cultivation technology development department of the Tsumura Crude Drug Headquarters in Japan, expressed his gratitude to the production area through online form, and also hoped that the production company could continue to uphold the spirit of enterprise, strictly abide by the quality of crude drugs, and create more high-quality and good medicinal materials.
▲Mr.Nosi, General Manager of the Crude Drugs Business Department of the Tsumura Crude Drugs Headquarters in Japan
Mr.Nosi, General Manager of the Crude Drugs Business Department of the Tsumura Crude Drugs Headquarters in Japan, expressed his gratitude to the participants at the meeting and expressed his hope that they will continue to work together to continue to provide safety for patients.
▲Makoto Saito, deputy general manager of China Medico
Makoto Saito, deputy general manager of China Medico, expressed his gratitude to the production company that has been supporting and helping. What has changed is the continuous improvement of the quality standards of medicinal materials, and the requirements for GACP promotion and drug use have been continuously strict, but what remains unchanged is to ensure the safe and stable supply of medicinal materials, and hopes to work together with the producing companies for common development.
▲Li Gang, executive director/general manager of China Medico
Finally, Li Gang, executive director/general manager of China Medico, made a concluding speech. Mr. Li said that in the past year, in the more severe market environment, the company's operation is still rising rapidly, and the achievements are inseparable from the support and help of the companies in the origins, and he would like to express his heartfelt thanks to the companies in the origins.
Mr. Li pointed out that the relationship between the company, the companies and farmers in various producing areas is interdependent, and we must always insist on supporting each other and standing together through thick and thin. He emphasized that first, it is necessary to strictly implement the contract, complete the supply demand according to the agreed price and time, ensure the continuous and stable supply of medicinal materials, and fulfill corporate social responsibility; Second, regarding the work of insect pests, it is necessary to make efforts from the source, strengthen the quality control of medicinal materials in the whole industrial chain links such as planting, processing, and storage, and strictly ensure the quality standards of medicinal materials. Finally, Mr. Li encouraged everyone to strengthen their confidence, and hoped to work together with various production companies to work together to achieve the mission of "letting Chinese use real good Chinese medicine".